STOCK TITAN

Covalon Announces Voting Results from Fiscal 2023 Annual Meeting of Shareholders

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Covalon Technologies Ltd. announces successful results of its Fiscal 2023 Annual Meeting of Shareholders, with all items of business approved. The voting results for the election of the Board of Directors and the appointment of auditors are detailed, showing high approval rates.
Positive
  • Successful approval of all items of business at Covalon's Fiscal 2023 Annual Meeting of Shareholders.
  • High voting percentages for the election of the Board of Directors and the appointment of auditors.
  • Detailed breakdown of the voting results for each nominee and the auditor.
  • Availability of further details on the voted matters in the Company's management information circular.
  • Recording of the AGM and management's presentation accessible on Covalon's website.
Negative
  • None.

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the results of the matters voted upon at its Fiscal 2023 Annual Meeting of Shareholders (“AGM”) held March 6, 2024.

Shareholders voted in favour of all items of business and each item of business was approved by the requisite number of votes. The matters included the election of the Board of Directors and the appointment of auditors. The total number of shares represented, either in person or by proxy, totaled 10,665,029 or 43.232%. The voting results are detailed below.

1) The Election of the Board of Directors

Name of Nominee

Votes FOR

%

Votes WITHHELD

%

Brent Ashton

10,481,118

99.811

19,800

0.189

Amir Boloor

10,405,326

99.090

95,592

0.910

Joseph Cordiano

10,363,626

98.693

137,292

1.307

Martin Goldfarb

10,350,326

98.566

150,592

1.434

Samantha Nutt

10,435,784

99.380

65,134

0.620

Abe Schwartz

10,182,126

96.964

318,792

3.036

Ron Smith

10,373,626

98.788

127,292

1.212

2) The Appointment of the Auditor

 

Votes FOR

%

Votes WITHHELD

%

PricewaterhouseCoopers,

LLP

10,661,208

99.983

1,800

0.017

Final voting results of all matters voted on at the meeting will be filed on SEDAR+ at http://www.sedarplus.ca/ and further details of the voted matters can be found in the Company’s management information circular January 30, 2024.

A recording of the AGM and a copy of management’s presentation are available on Covalon’s website at https://ir.covalon.com/events-and-presentations/events/event-details/2024/Annual-Meeting-of-Shareholders-2024-IEG2Kp8KHg.

Those interested in learning more about Covalon’s solutions may visit www.covalon.com or follow Covalon on LinkedIn, Facebook, or Instagram.

About Covalon

Covalon is a patient-driven medical device company, that provides innovative and cost-effective healthcare solutions that aim to help reduce pain, prevent infection, and promote healing. Through a strong portfolio of patented technologies and solutions for advanced wound care, infection control, and medical device coatings, we offer innovative, gentle and more compassionate options to aid patients on their healing journey. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon’s name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur”, or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management’s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the “Risks and Uncertainties” section of our management’s discussion and analysis of financial condition and results of operations for the year ended September 30, 2023, which is available on the Company’s profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.

To learn more about Covalon:

Investor Relations, Covalon Technologies Ltd.

Email: investors@covalon.com

Website: https://covalon.com/

Source: Covalon Technologies Ltd.

FAQ

What were the results of Covalon Technologies Ltd.'s Fiscal 2023 Annual Meeting of Shareholders?

Covalon announced successful voting results with all items of business approved.

How many shares were represented at the AGM?

A total of 10,665,029 shares, equivalent to 43.232%, were represented at the AGM.

Who were the nominees for the Election of the Board of Directors?

Nominees included Brent Ashton, Amir Boloor, Joseph Cordiano, Martin Goldfarb, Samantha Nutt, Abe Schwartz, and Ron Smith.

What was the voting percentage for the Appointment of the Auditor?

PricewaterhouseCoopers, LLP received a high approval rate of 99.983% for the Appointment of the Auditor.

Where can further details on the voted matters be found?

Additional details on the voted matters can be accessed in the Company's management information circular.

COVALON TECHS LTD

OTC:CVALF

CVALF Rankings

CVALF Latest News

CVALF Stock Data

61.66M
12.79M
48.7%
Biotechnology
Healthcare
Link
United States of America
Mississauga